Amid the global political and economic turmoil taking place, one small pharma story got much less attention than it should have.
Not for the first time, the ombudsman for the European Union, Emily O’Reilly, issued a statement calling on the European Medicines Agency (EMA) and AbbVie to cease the withholding of trial data for blockbuster drug, Humira (adalimumab). The company took the EMA to court in 2013 to prevent the publication of data, but reached a compromise, of sorts, whereby redacted documents could be released.